In a report released yesterday, Ryan Daniels from William Blair reiterated a Buy rating on Medpace Holdings (NASDAQ: MEDP). The company’s shares closed yesterday at $57.83.
According to TipRanks.com, Daniels is a 4-star analyst with an average return of 20.6% and a 54.0% success rate. Daniels covers the Services sector, focusing on stocks such as Healthcare Services, Envision Healthcare, and Cotiviti Holdings.
Currently, the analyst consensus on Medpace Holdings is a Moderate Buy with an average price target of $56.33.
See today’s analyst top recommended stocks >>
Medpace Holdings’ market cap is currently $2.04B and has a P/E ratio of 41.31. The company has a Price to Book ratio of 3.78.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medpace Holdings, Inc. engages in the research, development, and trading of medical device and pharmaceutical products. Its services include medical affairs, clinical trial management, study feasibility, study-start-up, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August J. Troendle in July 1992 and is headquartered in Cincinnati, OH.
